Committed to improving outcomes in Cardiogenic Shock and Protected PCI through excellence in education.
Use this patient transfer checklist and documentation when transferring a patient supported with an Impella® device from the “Spoke” hospital to the “Hub” hospital. Completing the patient transfer checklist ensures the best possible outcome for the patient during the transfer process.
Dr. Susan Joseph, Advanced Heart Failure Specialist from Baylor University Medical Center, discusses perspectives on management of Impella patients in critical care units, particularly the use of invasive hemodynamic monitoring. PA catheters, or right heart catheterization, provide a minute to minute constant source of information about a patient with shock and their filling pressures, pulmonary … Continue reading “Importance of Right Heart Catheterization”
- This retrospective study evaluated observational data of patients receiving either early or delayed initiation of Impella for the management of acute myocardial infarction complicated by cardiogenic shock (AMICS).
- Receiving mechanical circulatory support (MCS) prior to percutaneous coronary intervention (PCI) compared with post-PCI initiation was associated with a higher survival rate to discharge among AMICS patients.
- Overall survival to discharge for the cohort was 44%.
- Additionally, early initiation of MCS at the first signs of shock and before inotropes, vasopressors, and PCI correlated with a higher rate of survival.
This instructional video provides the steps to insert the Impella 2.5® or Impella CP® with the assistance of the Automated Impella Controller into the femoral artery. Subscribe, Tweet this or join the conversation by following us on Twitter: @ProtectedPCI AIC-007-17 To learn more about the Impella® platform of heart pumps, including important risk and safety information associated with the … Continue reading “Femoral Insertion of Impella 2.5/CP with AIC”
What is Cardioprotection? Dr. Bill O’Neill of Henry Ford Health System and co-principle investigator of the FDA STEMI-DTU safety and feasibility RCT, discusses the concept of cardioprotection. Cardioprotection is a cellular response to protect the myocardium from suffering irreversible injury. IMP-449 Subscribe, or join the conversation by following us on Twitter: @ProtectedPCI To learn more about … Continue reading “Dr. Bill O’Neill explains the concept of cardioprotection”
2018 was an exciting, educational year full of new Impella® data including expanded FDA indications, results from the STEMI-DTU trial, and new Protected PCI and cardiogenic shock case studies. Now that we are into 2019, we are looking back on 2018 with a compilation of the most viewed videos on ProtectedPCI.com. Enjoy the recap, and check back regularly … Continue reading “ProtectedPCI.com’s Top Videos from 2018”
Reference: J Am Coll Cardiol 2018; 72:1972-80 Cardiogenic shock continues to be the leading cause of death in patients with acute myocardial infarction (AMI).1 Despite implementation of guideline-recommended early revascularization, mortality rates in AMI complicated by cardiogenic shock (AMICS) remains constant at about 50%. Given that about 60,000 patients with AMI develop CS every year,2 … Continue reading “Improving Survival in Cardiogenic Shock by Adopting a Uniform Approach to Systems of Care”
Subscribe here for updates from ProtectedPCI.com during TCT 2018. Abiomed Booth Hours – Booth #829 Visit Abiomed’s booth for demonstrations, clinical data review and opportunities to engage in hands-on simulations of the Impella platform. Saturday September 22, 2018: 8:00 AM – 5:00 PM Sunday, September 23, 2018: … Continue reading “2018 TCT: More Than 30 Sessions Showcasing Impella® Technology”
- This meta-analysis evaluated 6 randomized controlled trials to determine outcome differences between percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) among patients with unprotected left main coronary artery disease ([ULMCAD] n = 4686).
- Compared with CABG, PCI correlated with significantly lower rates of 30-day stroke (P = 0.007), death or MI (P = 0.04), or all-cause death, MI, or stroke (P = 0.01).
- In the PCI group, there was a significantly lower rate of 30-day stroke incidence (P = 0.007) and all-cause death, MI, or stroke (P = 0.01).
- The authors found no significant difference in outcomes at long-term follow-up (median 39 months) between the two groups.